Chesapeake Wealth Management grew its position in Amgen, Inc. (NASDAQ:AMGN) by 6.7% in the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 8,637 shares of the medical research company’s stock after purchasing an additional 543 shares during the period. Chesapeake Wealth Management’s holdings in Amgen were worth $1,640,000 as of its most recent SEC filing.
A number of other hedge funds and other institutional investors have also recently bought and sold shares of AMGN. Ruggie Capital Group boosted its holdings in shares of Amgen by 297.1% in the fourth quarter. Ruggie Capital Group now owns 135 shares of the medical research company’s stock valued at $26,000 after acquiring an additional 101 shares in the last quarter. Capital Financial Planning LLC bought a new position in shares of Amgen in the fourth quarter valued at approximately $27,000. Massey Quick Simon & CO. LLC boosted its holdings in shares of Amgen by 710.5% in the fourth quarter. Massey Quick Simon & CO. LLC now owns 154 shares of the medical research company’s stock valued at $30,000 after acquiring an additional 135 shares in the last quarter. Next Capital Management LLC bought a new position in shares of Amgen in the fourth quarter valued at approximately $33,000. Finally, Essex Investment Management Co. LLC bought a new position in shares of Amgen in the fourth quarter valued at approximately $39,000. Hedge funds and other institutional investors own 80.65% of the company’s stock.
In related news, Director Ronald D. Sugar sold 2,000 shares of the stock in a transaction that occurred on Wednesday, May 1st. The shares were sold at an average price of $175.73, for a total transaction of $351,460.00. Following the completion of the sale, the director now directly owns 15,092 shares of the company’s stock, valued at $2,652,117.16. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Over the last three months, insiders have sold 6,000 shares of company stock valued at $1,115,580. Company insiders own 0.25% of the company’s stock.
AMGN stock opened at $169.91 on Monday. Amgen, Inc. has a 12 month low of $166.30 and a 12 month high of $210.19. The company has a market cap of $103.63 billion, a P/E ratio of 11.80, a price-to-earnings-growth ratio of 2.24 and a beta of 1.15. The company has a quick ratio of 2.53, a current ratio of 2.77 and a debt-to-equity ratio of 2.71.
Amgen (NASDAQ:AMGN) last released its earnings results on Tuesday, April 30th. The medical research company reported $3.56 EPS for the quarter, beating the consensus estimate of $3.45 by $0.11. Amgen had a net margin of 34.00% and a return on equity of 71.02%. The business had revenue of $5.56 billion during the quarter, compared to analyst estimates of $5.55 billion. During the same period in the prior year, the business earned $3.47 earnings per share. The business’s quarterly revenue was up .1% on a year-over-year basis. Equities analysts predict that Amgen, Inc. will post 13.94 earnings per share for the current fiscal year.
The firm also recently announced a quarterly dividend, which will be paid on Friday, June 7th. Investors of record on Friday, May 17th will be paid a dividend of $1.45 per share. This represents a $5.80 annualized dividend and a yield of 3.41%. The ex-dividend date is Thursday, May 16th. Amgen’s dividend payout ratio is presently 40.28%.
ILLEGAL ACTIVITY WARNING: This article was first reported by Baseball Daily News and is owned by of Baseball Daily News. If you are accessing this article on another publication, it was illegally copied and republished in violation of international copyright and trademark law. The original version of this article can be accessed at https://www.baseballdailydigest.com/news/2019/05/20/amgen-inc-amgn-holdings-lifted-by-chesapeake-wealth-management.html.
Amgen Company Profile
Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. It offers products for the treatment of oncology/hematology, cardiovascular, inflammation, bone health, and neuroscience. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta, a pegylated protein to treat cancer patients; Prolia to treat postmenopausal women with osteoporosis; Aranesp to treat anemia; Xgeva for skeletal-related events prevention; Sensipar/Mimpara products to treat sHPT in chronic kidney disease; and EPOGEN to treat a lower-than-normal number of red blood cells.
See Also: What is the Quick Ratio?
Want to see what other hedge funds are holding AMGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amgen, Inc. (NASDAQ:AMGN).
Receive News & Ratings for Amgen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen and related companies with MarketBeat.com's FREE daily email newsletter.